GSK beats Q4 earnings estimates, lifts 2031 sales target - MSN

(Reuters) - GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines ...


Install CouponFollow Chrome Extension   CouponFollow Extension

3%
OFF

GSK Beats Q4 Earnings Estimates, Lifts 2031 Sales Target - MSN

2 weeks from now

(Reuters) - GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines ...

msn.com

6%
OFF

GSK Launches $2.5 Billion Buyback, Lifts Sales Target After Stellar ...

2 weeks from now

3 days ago  · GSK's Q4 EPS and sales beat estimates Shares jump 6% R&D investment to focus on speciality medicines Feb 5 (Reuters) - GSK (GSK.L), opens new tab launched a 2 billion …

reuters.com

$2
OFF

GSK Launches $2.5 Billion Buyback, Lifts Sales Target After ... - MSN

2 weeks from now

It reported core earnings per share of 23.2 pence on sales of 8.12 billion pounds for the quarter ended Dec. 31, compared with 19 pence on sales of 7.75 billion pounds expected by analysts …

msn.com

$2
OFF

GSK Beats On Q4 Earnings & Sales, Stock Up On Raised Long-Term …

2 weeks from now

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

yahoo.com

1%
OFF

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 Billion …

2 weeks from now

2 days ago  · Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The …

yahoo.com

10%
OFF

GSK Q4 Earnings: Revenue And EPS Beat, Initiates $2.5 ... - Benzinga

2 weeks from now

3 days ago  · GSK reported Q4 sales of $10.40B, surpassing estimates of $9.58B, while core EPS of $0.59 beat the consensus of $0.43 despite a 10% decline. Vaccine sales fell 14% to …

benzinga.com

$50
OFF

GSK Surges After Bumping Its 2031 Outlook To North Of $50 Billion

2 weeks from now

2 days ago  · Specifically, GSK called for more than 40 billion pounds in 2031 sales, up from its previous outlook for north of 38 billion pounds. That translates to $50.07 billion, up from …

investors.com

3%
OFF

GSK Beats Q4 Earnings Estimates, Lifts 2031 Sales Target

2 weeks from now

3 days ago  · (Reuters) - GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness …

marketscreener.com

£40
OFF

GSK Delivers Strong 2024 Performance With Further Improvement …

2 weeks from now

3 days ago  · GSK delivers strong 2024 performance with further improvement to long-term growth outlook. Download ... 2031 sales outlook increased to more than £40 billion (previously >£38 …

gsk.com

$50
OFF

GSK Lifts 2031 Sales Target After Better-than-expected Q4 - MSN

2 weeks from now

(Reuters) - GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty ...

msn.com

$50
OFF

GSK Lifts 2031 Sales Target After Better-than-expected Q4

2 weeks from now

3 days ago  · (Reuters) – GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily …

srnnews.com

3%
OFF

GSK Beats Q4 Earnings Estimates, Lifts 2031 Sales Target

2 weeks from now

3 days ago  · (Reuters) - GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness …

globalbankingandfinance.com

3%
OFF

GSK Beats Q4 Earnings Estimates, Lifts 2031 Sales Target

2 weeks from now

3 days ago  · GSK beats Q4 earnings estimates, lifts 2031 sales target. GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in …

public.com

£40
OFF

GSK Boosts 2031 Sales Target To £40 Billion After S... | DeepNewz

2 weeks from now

3 days ago  · GSK Plc reported better-than-expected fourth-quarter earnings for 2024, with adjusted earnings per share of £0.23, surpassing the estimated £0.20. Revenue reached …

deepnewz.com

$0.59
OFF

GSK (GSK) Tops Q4 Earnings And Revenue Estimates - MSN

2 weeks from now

GSK (GSK) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.53 per share. This compares to earnings of $0.72 per share a year ago. These …

msn.com

3%
OFF

GSK Launches $2.5 Bln Buyback, Lifts Sales Target After Stellar Q4

2 weeks from now

GSK expects revenue to increase between 3% and 5% in 2025 despite forecasting vaccine sales to fall by a "low single-digit" percentage. The company lifted its 2031 sales forecast to more …

msn.com

$2
OFF

GSK Issues $2.5 Billion Buyback, Raises Midterm Outlook After …

2 weeks from now

3 days ago  · By Helena Smolak GSK plans to buy back $2.50 billion in shares and raised its midterm sales target, citing promising pipeline developments. ... GSK beats Q4 earnings …

marketscreener.com

$2
OFF

GSK Beats On Q4 Earnings & Sales, Stock Up On Raised Long-Term …

2 weeks from now

2 days ago  · GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion. GSK Beats on …

nasdaq.com

$2
OFF

GSK Launches $2.5 Billion Buyback, Lifts Sales Target After Stellar Q4

2 weeks from now

3 days ago  · (Reuters) -GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales …

yahoo.com

FAQs about GSK beats Q4 earnings estimates, lifts 2031 sales target - MSN Coupon?

Will GSK increase its sales to $50 billion?

For more news like this visit The Economic Times. GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make up for pressures on its vaccines revenue. ...

Will GSK buy back 2 billion pounds worth of shares?

The company reported core earnings per share of 23.2 pence on sales of 8.12 billion pounds for the quarter ended Dec. 31, compared with 19 pence on sales of 7.75 billion pounds expected by analysts in an LSEG poll. GSK also said it would buy back 2 billion pounds worth of shares over the next 18 months. ...

What was GSK's fourth-quarter sales?

Wednesday, GSK Plc (NYSE: GSK) reported fourth-quarter sales of $10.40 billion (8.12 billion Sterling Pounds), up 1% year-over-year and up 4% on constant currency. The analysts estimated sales of $9.58 billion. ...

How much will GSK revenue increase in 2025?

GSK expects revenue to increase between 3% and 5% in 2025 despite forecasting vaccine sales to fall by a "low single-digit" percentage. The company lifted its 2031 sales forecast to more than 40 billion pounds, from 38 billion pounds targeted previously. ...

Why did GSK's fourth-quarter earnings top estimates?

GSK's fourth-quarter earnings topped estimates as strength in its HIV and oncology portfolio offset a fall in sales of its respiratory syncytial virus (RSV) and shingles shots. ...

Why did GSK raise its 2031 sales target?

(Reuters) - GSK posted a better-than-expected fourth quarter on Wednesday and lifted its 2031 sales target to nearly $50 billion as the British drugmaker aims to invest heavily in its specialty medicines to offset weakness in vaccine. ...

Install CouponFollow Extension on Chrome

Install the CouponFollow extension to search for discount codes when shopping the fastest!

Install CouponFollow Chrome Extension   Install CouponFollow Chrome Extension